Endocrine Abstracts

There is increasing evidence that alterations in alternative splicing can be linked to key tumor features in cancer. Dysregulations in the splicing machinery constitute the underlying cause in many of these alterations and, consequently, splicing and its control are emerging as a novel and transversal cancer hallmark, due to its association with different dysfunctions of tumor cells. In line with this, we discovered the existence of aberrantly spliced variants of somatostatin ...

Dysregulation of the splicing machinery is emerging as a novel cancer hallmark due to its association with multiple dysfunctions in tumor cells. An inappropriate function of the components of this machinery (spliceosome) could be primarily linked with the generation of tumor-associated aberrant splicing variants. In line with this, we have previously reported that overexpression of aberrantly spliced variants of somatostatin receptor 5 (sst5TMD4) and ghrelin (In1-ghrelin) is d...

Pancreatic neuroendocrine tumors (panNETs) are the second most common neoplasm of the pancreas. panNETs arise from cells of the pancreatic islets and comprise a diverse and heterogeneous group of neoplasms. This hampers their systematic study, and the identification of common molecular signatures that might facilitate a better diagnosis of the disease, and the development of efficient therapeutic approaches. Indeed, there are no clinical, biochemical, anatomopathological, immu...

Pancreatic neuroendocrine tumors (PanNETs) are heterogeneous neoplasms with a relatively low but increasing incidence, mainly due to the difficulty in diagnosing this disease in its early stages. This notably complicates the treatment of this pathology and leads to a poor prognosis. One of the main reasons for this problem is the lack of adequate diagnostic biomarkers as well as effective therapeutic targets. In this sense, there is still a limited knowledge about alternative ...

Introduction: Emerging evidence indicates that dysregulation of alternative splicing represents a new hallmark of cancer. This dysregulation may arise from mutations or altered expression of specific components of the splicing machinery. To date, splicing machinery status has not been studied in lung neuroendocrine neoplasms: typical and atypical pulmonary carcinoids.Objectives: Here, we aimed to analyzing the splicing machinery in pulmonary carcinoids a...

IntroductionDysregulation of alternative splicing is emerging as a new hallmark of cancer. This dysregulation may originate from mutations and/or altered expression of specific components of the splicing machinery. Indeed, our group has shown that the expression profile of the splicing machinery is altered in several types of cancer, including endocrine-related cancers. However, to date, the status of alternative splicing and its putative dysregulation h...